Epitalon vs MOTS-c at a glance
| Property | Epitalon | MOTS-c |
|---|---|---|
| Structure | Synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG) | 16-amino-acid peptide encoded in mitochondrial DNA |
| Origin | Analog of Epithalamin, a bovine pineal gland extract | Discovered inside the mitochondrial 12S rRNA gene, USC, 2015 |
| Primary mechanism studied | Telomerase reactivation in human fibroblasts | AMPK activation via a spike in endogenous AICAR |
| Research focus | Lifespan, telomere length, retinal and neural aging | Insulin sensitivity, obesity, exercise physiology |
| Strongest animal data | 11-31% lifespan increase across four species, 1998 | Reversed diet-induced obesity and insulin resistance in mice, 2015 |
| Human data | 266-patient mortality trial, published 2003 | Observational cohorts only; first interventional trial began recruiting in 2026 |
| Approved drug product | None | None |
A pineal tetrapeptide against a mitochondrial microprotein
Epitalon vs MOTS-c is a comparison between two peptides that come from opposite ends of the cell. Epitalon is a synthetic four-amino-acid peptide built to mimic Epithalamin, an extract of bovine pineal tissue that Vladimir Khavinson's laboratory in St. Petersburg had studied since the 1980s. The sequence, Ala-Glu-Asp-Gly, is short enough to synthesize cheaply and specific enough to reproduce several of the extract's effects in later experiments.
MOTS-c starts from a stranger premise. Mitochondria carry their own small genome, and for decades biologists assumed that genome coded for the standard set of respiratory-chain proteins and nothing else. In 2015, Changhan Lee and Pinchas Cohen's group at the University of Southern California found a 16-amino-acid open reading frame hiding inside the mitochondrial 12S rRNA gene and named the peptide it produced MOTS-c, for mitochondrial open reading frame of the 12S rRNA type c (Lee et al., Cell Metab, 2015).
Epitalon's research history runs through pineal biology and telomeres. MOTS-c's runs through mitochondrial genetics and exercise metabolism. The two fields rarely overlap.
What the telomerase and lifespan data show for Epitalon
The finding that put Epitalon on the map came from a 2003 study using telomerase-negative human fetal fibroblasts. Khavinson's group added the peptide to the culture and reported induction of the catalytic telomerase subunit, measurable telomerase enzymatic activity, and telomere elongation in cells that had shown none of that activity beforehand (Khavinson et al., Bull Exp Biol Med, 2003). That is an in vitro result in one fibroblast line, not evidence that an injected peptide reaches the same cells in a living body and produces the same effect. The original paper does not close that gap.
The lifespan data goes back further and covers more species. A 1998 paper measured survival in Drosophila melanogaster, SHR mice, C3H/Sn mice, and LIO rats given the related pineal peptide preparation Epithalamin, and found mean lifespan increases of 11 to 31 percent across the four groups, with mortality rate reductions of 52 percent in the flies, 52 percent in the rats, and 27 percent in the C3H mice (Anisimov, Mylnikov, Khavinson, Mech Ageing Dev, 1998). A follow-up study in female SHR mice extended the same research program to spontaneous tumor incidence alongside the aging biomarkers (Anisimov et al., Biogerontology, 2003).
Epitalon's human data is older and larger than most peptides get. Khavinson and Morozov followed 266 elderly and older patients for six to eight years, comparing a thymic peptide called Thymalin, Epithalamin, the two combined, and an untreated group. Mortality fell 1.6 to 1.8-fold in the Epithalamin group, 2.5-fold in the combined group, and 4.1-fold in patients who received six annual courses of both peptides together (Khavinson, Morozov, Neuro Endocrinol Lett, 2003, n=266). The trial predates the reporting standards modern journals require, and no Western group has repeated it since, so the finding stands alone rather than replicated.
A more recent study looked at neural tissue instead of lifespan. Researchers applied Epitalon to human gingival mesenchymal stem cells in 2020 and measured a 1.6 to 1.8-fold rise in four neurogenic marker genes, proposing that the peptide binds linker histones and shifts chromatin toward a more transcriptionally active state (Khavinson et al., Molecules, 2020). That paper and the fibroblast telomerase study point at the same general idea, that Epitalon changes what genes a cell expresses, but they used different cell types and different endpoints, so neither confirms the other directly.
What the metabolic and exercise data show for MOTS-c
Lee's original 2015 paper gave mice daily intraperitoneal injections of synthetic MOTS-c for five days and found the peptide raised endogenous AICAR, a purine metabolism intermediate, more than 20-fold, which activated AMPK in skeletal muscle and prevented high-fat-diet mice from developing obesity and insulin resistance. A 2018 follow-up traced part of the mechanism further: under metabolic stress, MOTS-c moves into the nucleus and regulates transcription of genes involved in the cellular antioxidant response, rather than acting only in the cytoplasm as first assumed (Kim, Son, Benayoun, Lee, Cell Metab, 2018).
Human data on MOTS-c comes almost entirely from measuring the peptide people already carry, not from dosing them with more of it. A 2020 study of 104 healthy men across three age groups found circulating MOTS-c was 11 percent lower in middle age and 21 percent lower in older participants than in young men, even as MOTS-c expression inside skeletal muscle rose with age and correlated with a shift toward slow-twitch fiber composition (D'Souza et al., Aging, 2020, n=104). A separate study of 75 professional endurance athletes against 30 non-athlete controls found trained athletes carried significantly lower serum MOTS-c than sedentary controls, the opposite of what a simple exercise-raises-MOTS-c story would predict (Alser et al., Rev Cardiovasc Med, 2022, n=105).
A 2021 mouse study came closer to testing the peptide as an intervention. Researchers gave MOTS-c to mice three times a week starting late in life and measured improvements in grip strength, gait, and walking capacity relative to untreated old mice, alongside evidence that exercise itself triggers a rise in endogenous MOTS-c in skeletal muscle and plasma (Reynolds et al., Nat Commun, 2021). Those healthspan gains were measured in mice, which keeps the strongest interventional evidence for MOTS-c on the animal side of the ledger for now.
Human trial evidence: decades apart
The gap between these two peptides in humans is not about whose data reads better. It is about what kind of human data exists at all. Epitalon's 266-patient mortality study, unreplicated and dated by modern standards, is still an interventional study in people. MOTS-c has no completed interventional human trial of any size.
The closest thing on record is an observational cohort of 120 type 2 diabetic patients with coronary artery disease that tracked naturally occurring MOTS-c levels against platelet reactivity and mortality, rather than giving anyone the peptide (ClinicalTrials.gov NCT04027712).
That changes only in the last stretch of the queue. A Phase 2, randomized, double-blind trial registered on ClinicalTrials.gov began recruiting 120 adults with prediabetes and overweight in 2026, testing 12 weeks of subcutaneous MOTS-c against placebo with insulin sensitivity on an oral glucose tolerance test as the primary endpoint (ClinicalTrials.gov NCT07505745). Until that trial reports, comparing the two peptides on human evidence means comparing one old, small, unreplicated trial against zero completed trials, not a genuine head-to-head.
Storage, sourcing, and research handling in Indonesia
Neither peptide has an approved drug product anywhere, and both are supplied to laboratories as lyophilized powder that needs similar handling regardless of mechanism. Reconstituted Epitalon and MOTS-c should go straight into refrigeration. Bali and Jakarta's ambient humidity accelerates degradation faster than the temperate conditions most of the underlying stability data was collected in, a point the lyophilized peptide storage guide covers for tropical climates. Reconstitution technique, not compound choice, is the step most research protocols get wrong first, and the reconstitution guide walks through it for either peptide.
Under BPOM's framework for laboratory materials, both peptides are handled as research reagents rather than registered pharmaceuticals when supplied to labs across Indonesia. Anyone converting a published mcg or mg/kg figure from either peptide's animal literature into a concentration and draw volume for a specific vial can check the arithmetic with the dosing calculator instead of estimating by eye. For a full treatment of either compound on its own, see the Epitalon research overview and the MOTS-c research overview. MOTS-c is also listed in the compound catalog.